X4 Pharmaceuticals Inc at Stifel Healthcare Conference Transcript
I'm Stephen Willey, one of the senior biotech analysts here at Stifel. Glad to have with us for the next session Paula Ragan who is the Chief Executive Officer of X4 and the Chief Financial Officer, Adam Mostafa, is also in attendance as well. We're just going to have kind of an informal chat. If anyone has a question at any point, feel free to raise your hand. We'll try to get you acknowledged and get your questions asked and answered. Paula, not sure if you want to make any kind of opening comments before we get into Q&A.
Sure. We're -- so thank you for hosting. Thanks to the Stifel team for this conference. It's nice to be in person with everyone. And I think we're really excited about where the company is at. We're on the cusp of Phase 3 data. We just had a great readout in September and a broader indication. And certainly coming off the crazy biotech markets of 2022, we're in a really nice position for a successful 2023 and beyond. So great to be here
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |